Michelle R Lofwall Selected Research

Miosis

9/2021	Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.
11/2019	Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.
1/2017	Effects of Short-Term Oxycodone Maintenance on Experimental Pain Responses in Physically Dependent Opioid Abusers.
5/2016	Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
1/2016	Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.
12/2015	Safety of oral dronabinol during opioid withdrawal in humans.
11/2013	Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.
10/2012	Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.
10/2010	Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
12/2008	The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michelle R Lofwall Research Topics

Disease

31	Opioid-Related Disorders (Opiate Addiction) 05/2022 - 03/2010
10	Miosis 09/2021 - 12/2008
8	Pain (Aches) 11/2019 - 10/2010
6	Substance-Related Disorders (Drug Abuse) 01/2020 - 04/2005
5	Respiratory Insufficiency (Respiratory Failure) 09/2021 - 12/2008
5	Infections 01/2020 - 01/2013
4	Cocaine-Related Disorders (Cocaine Addiction) 06/2013 - 01/2007
3	Opiate Overdose 01/2019 - 04/2017
2	Tobacco Use Disorder (Nicotine Dependence) 01/2020 - 06/2014
2	Hallucinations (Hallucination) 01/2020 - 11/2006
2	Mental Disorders (Mental Disorder) 01/2017 - 12/2012
1	COVID-19 05/2022
1	Ataxia (Dyssynergia) 01/2020
1	Drug Overdose 01/2020
1	Drug Misuse 01/2020
1	Psychotic Disorders (Schizoaffective Disorder) 01/2020
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020
1	Weight Gain 09/2019
1	Postherpetic Neuralgia 01/2018
1	Epilepsy (Aura) 03/2017
1	Neoplasms (Cancer) 03/2017
1	Crohn Disease (Crohn's Disease) 01/2017
1	Arthritis (Polyarthritis) 01/2017
1	Chronic Pain 01/2017
1	Tachycardia (Tachyarrhythmias) 07/2016
1	Sinus Tachycardia 12/2015
1	Rhinorrhea 11/2013
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2013
1	Sneezing 11/2013
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2013
1	Anxiety Disorders (Anxiety Disorder) 12/2012
1	Mydriasis 10/2012
1	Exotropia (Exophoria) 12/2008

Drug/Important Bio-Agent (IBA)

23	Opioid Analgesics (Opioids)IBA 05/2022 - 04/2005
21	Buprenorphine (Subutex)FDA LinkGeneric 05/2022 - 03/2010
11	Pharmaceutical PreparationsIBA 09/2021 - 12/2012
8	Oxycodone (Oxycontin)FDA LinkGeneric 07/2021 - 06/2012
6	Analgesics (Analgesic Drugs)IBA 11/2019 - 09/2010
4	Tramadol (K315)FDA LinkGeneric 11/2013 - 09/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2018
3	Dronabinol (THC)FDA LinkGeneric 11/2019 - 12/2015
3	Naloxone (Narcan)FDA LinkGeneric 01/2019 - 01/2018
3	Cocaine (Cocaine HCl)IBA 01/2018 - 01/2013
3	Illicit Drugs (Recreational Drugs)IBA 01/2018 - 04/2005
2	Oxymorphone (Numorphan)FDA LinkGeneric 09/2021 - 01/2016
2	Gabapentin (Neurontin)FDA LinkGeneric 01/2020 - 01/2018
2	mu Opioid Receptors (mu Opioid Receptor)IBA 03/2019 - 12/2015
2	Narcotic Antagonists (Opioid Antagonists)IBA 01/2019 - 10/2018
2	Hydromorphone (Dilaudid)FDA LinkGeneric 01/2017 - 10/2012
2	Opiate AlkaloidsIBA 06/2012 - 12/2008
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2020
1	Pregabalin (Lyrica)FDA Link 01/2020
1	AticaprantIBA 01/2020
1	Nicotine FDA Link 01/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2020
1	Cannabinoid Receptor AgonistsIBA 11/2019
1	Methadone (Dolophine)FDA LinkGeneric 09/2019
1	insulin receptor-related receptor (IRR)IBA 01/2019
1	Caffeine (No Doz)FDA LinkGeneric 01/2018
1	Delayed-Action PreparationsIBA 01/2018
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2018
1	Therapeutic UsesIBA 03/2017
1	CannabinoidsIBA 07/2016
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 07/2016
1	Aripiprazole (Abilify)FDA Link 06/2014
1	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 06/2013
1	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2012
1	Naltrexone (ReVia)FDA LinkGeneric 10/2012
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 06/2012
1	Naloxone Drug Combination Buprenorphine FDA Link 08/2011
1	CatecholaminesIBA 09/2010
1	Heroin (Diamorphine)IBA 12/2008
1	Ketamine FDA LinkGeneric 11/2006

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2019 - 01/2007
2	Therapeutics 01/2020 - 11/2019
2	Self Administration (Administration, Self) 01/2020 - 08/2012
2	Analgesia 11/2019 - 01/2017
1	Injections 11/2021
1	Length of Stay 01/2020
1	Drug Tapering 12/2015
1	Opiate Substitution Treatment 01/2013